Page 517 - fbkCardioDiabetes_2017

Cardio Diabetes Medicine 2017 493

after treatment with potent statin therapy: an analysis from the JUPITER
trial. Lancet. 2010 Jul 31;376(9738):333-9.
3. Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residu-
al cardiovascular risk: There is need for substantial improvement. Int J
Cardiol. 2016 Dec 15;225:184-196. doi: 10.1016/j.ijcard.2016.09.075.
4. Cupido AJ, Reeskamp LF, Kastelein JJP. Novel lipid modifying drugs to lower
LDL cholesterol. Curr Opin Lipidol. 2017 Aug;28(4):367-373
5. Abifadel M, Elbitar S, El Khoury P, Ghaleb Y, Chémaly M, Moussalli ML,
Rabès JP, Varret M, Boileau C. Living the PCSK9 adventure: from the
identification of a new gene in familial hypercholesterolemia towards a
potential new class of anticholesterol drugs. Curr Atheroscler Rep. 2014
Sep;16(9):439.
6. Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW,
Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos
RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators.. Lipid-Reduction
Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J
Med. 2017 Apr 20;376(16):1517-1526
7. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall
T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein
JJ. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL
Cholesterol. N Engl J Med. 2017 Apr 13;376(15):1430-1440.
8. Di Bartolo BA, Duong M, Nicholls SJ. Clinical trials with cholesteryl ester
transfer protein inhibitors. Curr Opin Lipidol. 2016 Dec;27(6):545-549.
9. Zakiev E, Feng M, Sukhorukov V, Kontush A. HDL-Targeting Therapeutics:
Past, Present and Future. Curr Pharm Des. 2017;23(8):1207-1215.
10. Gryn SE, Hegele RA. Novel therapeutics in hypertriglyceridemia. Curr Opin
Lipidol. 2015 Dec;26(6):484-91.
11. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes
SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL. Targeting
APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014
Dec 4;371(23):2200-6.
12. Schreml J, Gouni-Berthold I. Apolipoprotein(a) Antisense Oligonucleotides:
A New Treatment Option for Lowering Elevated Lipoprotein(a)? Curr Pharm
Des. 2017;23(10):1562-1570.

Cardio Diabetes Medicine